[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05108519":3,"trial-entities:NCT05108519":78,"trial-summary:NCT05108519":83},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":34,"secondary_outcomes":39,"sex":40,"minimum_age":23,"maximum_age":23,"healthy_volunteers":15,"eligibility_criteria":41,"std_ages":47,"locations":51,"central_contacts":69,"overall_officials":70,"references":73,"see_also_links":74},"NCT05108519","PA18-1070","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","RECRUITING","2027-02-02","2026-08","2026-08-10","2019-04-08","M.D. Anderson Cancer Center","OTHER",false,"This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.","PRIMARY OBJECTIVE:\n\nI. To explore the incidence of clinical complications associated with anti-VEGF-related therapies in cancer patients treated at Emory University and the University of Texas M.D. Anderson Cancer Center (MDACC).\n\nSECONDARY OBJECTIVES:\n\nI. To explore the correlation of clinical response rates to a novel blood pressure scoring system in cancer patients treated with anti-VEGF-related therapies.\n\nII. To explore the correlation of objective response to each toxicity grade 3 or higher in cancer patients treated with anti-VEGF-related therapies.\n\nIII. To investigate the validity of a novel multi-parameter-based blood pressure scoring system and to determine if the new scoring method is concordant with the current Common Terminology Criteria for Adverse Events (CTCAE) method.\n\nOUTLINE:\n\nPatients' medical records are reviewed.",[19,20],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm",[],"OBSERVATIONAL",null,[],{"count":26,"type":27},170,"ESTIMATED",[29],{"type":14,"name":30,"description":31,"armGroupLabels":32},"Electronic Health Record Review","Medical records are reviewed",[33],"Observational (medical records review)",[35],{"measure":36,"description":37,"timeFrame":38},"Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)","For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value.","Up to 5 years",[],"ALL",{"inclusion":42,"exclusion":45,"raw_text":46},[43,44],"Patients must be able to understand and be willing to sign a written informed consent document","Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy",[],"Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy",[48,49,50],"CHILD","ADULT","OLDER_ADULT",[52],{"facility":53,"status":8,"city":54,"state":55,"zip":56,"country":57,"contacts":58,"geoPoint":66},"M D Anderson Cancer Center","Houston","Texas","77030","United States",[59,64],{"name":60,"role":61,"phone":62,"email":63},"Nicolas L. Palaskas","CONTACT","713-563-3532","nlpalaskas@mdanderson.org",{"name":60,"role":65},"PRINCIPAL_INVESTIGATOR",{"lat":67,"lon":68},29.76328,-95.36327,[],[71],{"name":72,"affiliation":13,"role":65},"Nicolas L Palaskas",[],[75],{"label":76,"url":77},"M D Anderson Cancer Center website","http:\u002F\u002Fwww.mdanderson.org",{"nct_id":4,"conditions":79,"biomarkers":82},[80,81],"Hematologic Neoplasm","Solid Neoplasm",[],{"nct_id":4,"found":84,"summary":85,"prompt_version":95},true,{"design":86,"status":87,"heading":88,"summary":89,"follow_up":90,"word_count":91,"commitments":92,"compensation":93,"drugs_mentioned":94},"This is an observational study that plans to enroll 170 participants. It is not a treatment study, but rather a review of existing medical records.","completed","Observational Study of Anti-VEGF Therapies in Cancer Patients","This observational study looks at complications and how cancer patients respond to anti-VEGF-related therapies. It aims to understand the side effects that may happen to people with advanced cancer receiving these treatments. Researchers will review medical records to see if there's a link between these side effects and how well the treatment works. You may be able to join if you have a hematopoietic and lymphoid cell neoplasm (blood cancer) or a malignant solid neoplasm (solid tumor cancer) and are receiving any anti-VEGF-related treatment. The study is observing side effects for up to 5 years. The current enrollment status is unclear.","The study will observe adverse events for up to 5 years.",101,"Your medical records will be reviewed. You will need to understand and sign a consent form.","Not stated in the trial record.",[],"v2"]